Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?

ABSTRACT:

Background

Tetrabenazine is the only US Food and Drug Administration-approved drug for Huntington's disease, and deutetrabenazine was recently tested against placebo. A switching-trial from tetrabenazine to deutetrabenazine is underway, but no head-to-head, blinded, randomized controlled trial is planned. Using meta-analytical methodology, the authors compared these molecules.

Methods

RCTs comparing tetrabenazine or deutetrabenazine with placebo in Huntington's disease were searched. The authors assessed the Cochrane risk-of-bias tool, calculated indirect treatment comparisons, and applied the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.

Results

The evidence network for this report comprised 1 tetrabenazine trial and 1 deutetra

SUBMITTER: Rodrigues FB 

PROVIDER: S-EPMC5573977 | biostudies-literature | 2017 Jul-Aug

REPOSITORIES: biostudies-literature